1. Introduction {#sec1}
===============

Multiple myeloma (MM) is a disorder of clonal proliferation of plasma cells. MM is defined as clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma, and one or more myeloma-defining features (hypercalcemia, renal failure, anemia, lytic bone lesions, ≥60% clonal bone marrow plasma cells, and serum-free light chain ratio ≥100) \[[@B1]\]. It constitutes 10--13% of all hematologic malignancies \[[@B2], [@B3]\] with an age-adjusted incidence rate of about 4--6 per 100,000 persons per year \[[@B2], [@B4]\]. Extramedullary disease (EMD) at the time of diagnosis of MM is rare (0.4% to 2%) \[[@B5], [@B6]\], but during the course of the disease, as many as 13% to 30% of the patients may exhibit extramedullary involvement \[[@B7], [@B8]\]. The most common extramedullary sites of plasmacytosis are the upper respiratory tract and sinonasal region \[[@B9]\]. However, on reviewing the literature, it is evident that virtually any organ can be affected \[[@B7], [@B10]\]. Involvement of multiple organs with EMD at the same time is extremely unusual. Of note, plasma cell disorders involving the female reproductive system, thyroid and breasts, are exceptionally uncommon.

Here, we present a case of multiple myeloma with extramedullary plasmacytomas of the female reproductive system, thyroid gland and breasts.

2. Case {#sec2}
=======

A 41-year-old female presented with pelvic pain, profuse menorrhagia, and severe symptomatic anemia (near syncope and shortness of breath). She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH/BSO) as the continuous bleeding was not responding to conservative measures and the patient had no further desire of fertility. Biopsy showed an infiltrate in the endomyometrium, fallopian tubes, and cervix of mature-appearing plasma cells that stained positive for CD56, CD38, CD79A, and MUM1 with lambda light chain restriction, consistent with plasmacytosis. Bone marrow (BM) biopsy demonstrated a hypercellular marrow and atypical plasmacytosis (25%) with lambda restriction. BM flow cytometry was positive for CD38, CD138, and CD19 and negative for CD56, CD20, and CD45 consistent with plasma cell neoplasm. FISH showed 46, \[XX\], female karyotype, positive for three copies of 1q21 including CKS1B gene. Free kappa and lambda light chain levels in urine were 39.9 (reference range 1.35--24.19) and 1.59 (0.24--6.66) with a kappa/lambda ratio of 25.09 (2.04--10.37). Free kappa and lambda light chains in serum were 12.6 (3.3--19.4) and 16.5 (5.7--26.3) with a kappa/lambda ratio of .76 (0.26--1.65). No M protein was detected in the SPEP or UPEP. The albumin level was 3.6, beta-2 microglobulin was 1.347 mg/L, and LDH was 163. The patient was diagnosed with nonsecretory multiple myeloma with extramedullary plasmacytoma (ISS stage I).

Around the time of TAH/BSO, the patient also reported progressively painful swelling on the left side of her neck accompanied with odynophagia, dysphagia, and hoarseness. CT of neck showed a left thyroid mass (7 × 5 × 7 cm) with irregular borders and a multinodular thyroid enlargement. ([Figure 1(a)](#fig1){ref-type="fig"}). Diagnostic incision biopsy demonstrated a very friable, irregular, malignant-appearing mass in the left lobe. A portion of the mass was removed and sent for analysis. Biopsy confirmed lambda-restricted plasma cell neoplasm involving the strap muscles ([Figure 1(b)](#fig1){ref-type="fig"}). The neoplastic plasma cells were positive for CD138, CD79a, CD45 (dim), MUM1, VS38C, and CD56. The patient remained clinically and biochemically euthyroid.

Whole body FDG-PET scan showed FDG uptake in a 4.4 × 4.7 cm mass with central necrosis within the left thyroid lobe ([Figure 1(c)](#fig1){ref-type="fig"}) along with mild FDG uptake within two right breast nodules. ([Figure 2(a)](#fig2){ref-type="fig"}). Breast U/S and mammography confirmed the nodules on the PET scan and showed other multiple bilateral nodules. Excision biopsy of the right breast nodule also showed lambda-restricted plasma cell neoplasm ([Figure 2(b)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}) positive for CD 56, CD138, CD79a, and VS38C. The patient also started complaining of lower extremity bone pain, but skeletal survey was negative.

The patient was started on bortezomib (Velcade), cyclophosphamide, and dexamethasone (VCD). After the first cycle, lenalidomide (Revlimid) was added to the regimen (RVCD). The patient completed a total of 1 cycle of VCD and 4 cycles of RVCD. Follow-up PET-CT scan done 6 weeks after the 5th cycle showed no evidence of active lesions. The patient had a clinical complete response (CR), so she proceeded with autologous stem cell transplantation (ASCT) 8 weeks after the 5th cycle of chemotherapy with high-dose melphalan conditioning. The patient tolerated the treatment well. She will be continued indefinitely on daily lenalidomide and alternate weekly bortezomib maintenance therapy and will be followed up with PET-CT scans.

3. Discussion {#sec3}
=============

This case poses multiple challenges right from its presentation to its treatment. First, profuse uterine bleeding is an extremely rare mode of initial presentation of MM \[[@B11]\]. Female reproductive organs, breasts, skeletal muscle, and thyroid gland, are exceedingly rare sites of EMD reported mostly in isolated case reports \[[@B11]--[@B13]\]. To the best of our knowledge, this is the only case report of MM with simultaneous involvement of the female reproductive system, thyroid and breasts.

Based on our current knowledge, multiple myeloma can lead to formation of soft tissue plasmacytomas most commonly from direct extension and local invasion of skeletal lesions. Rarely, MM can spread through hematogenous dissemination. Molecular mechanisms of EMD are poorly understood. However, reduced expression of cell adhesion molecules like VLA-4, CD44, P-selectin, and CD56, promotion of homing of myeloma cells by decreased expression of chemokine receptors like CCR1, CCR2, and CXCR4, and increased angiogenesis have been proposed as mechanisms \[[@B14]\]. In our case, the absence of bony lesions and the distance between sites of plasmacytosis points towards hematogenous spread.

Multiple studies have shown that extramedullary disease presages a poor prognosis and warrants more aggressive treatment strategies. A study of 1,003 myeloma cases by Varettoni et al. showed that EMD had an adverse prognostic impact on overall survival (hazard ratio 3.5) and progression-free survival (H.R 1.5), even more so when present at the time of diagnosis \[[@B7]\]. Usmani et al. also found that the 5-year overall survival in patients with extramedullary disease at diagnosis was shorter than in non-EMD patients (31% versus 59%). Presence of EMD at diagnosis was also associated with poor prognostic factors at baseline like anemia, thrombocytopenia, elevated centrosome index, and unfavorable cytogenetic abnormalities like MF molecular subtype (with translocation 14; 16 or 14; 20) and PR molecular subtype \[[@B15]\]. Our patient was positive for three copies of 1q21 with CKS1 gene which confers intermediate to high risk. An extra copy of 1q21 (CKS1B) is considered to be an adverse prognostic indicator. Gain/amplification of 1q21 increases the risk of MM progression, and incidence of amplification is higher in relapsed MM than in newly diagnosed patients \[[@B1], [@B16]\]. No other chromosomal abnormalities were found.

There are currently no established guidelines for the treatment of multiple myeloma with EMD. However, our current understanding is that patients with extramedullary myeloma eligible for stem cell transplantation could be treated with a triplet induction therapy followed by autologous stem cell transplantation (ASCT), triplet consolidation therapy, and maintenance with lenalidomide at least. For elderly patients not eligible for stem cell transplantation, bortezomib-melphalan-prednisone (VMP) or continuous lenalidomide-dexamethasone (Len-Dex) therapy may be done \[[@B1], [@B3], [@B16], [@B17]\]. Another treatment approach for aggressive disease with multiple plasmacytomas may be regimens like VDT-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide). ASCT may be done afterwards if eligible, and maintenance with bortezomib-based regimen will be done \[[@B1], [@B3], [@B16], [@B17]\] (see [Table 1](#tab1){ref-type="table"} for summary). In our case, given the aggressiveness of disease and atypical sites of involvement, a four-drug regimen (RVCD) was used, and maintenance therapy with both lenalidomide and bortezomib will be done. VDT-PACE regimen was a consideration, but our patient achieved a complete clinical response with RVCD therefore obviating its need.

As for the drugs used for treatment of MM with EMD, bortezomib has proven efficacy and may be incorporated in the multitude of treatment regimens \[[@B18]\]. Conversely, studies have mounted evidence against thalidomide\'s efficacy in treating multiple myeloma with EMD \[[@B19]\]. Emerging drugs include the immunomodulatory drug pomalidomide which is shown to be efficacious even against the extramedullary component \[[@B6]\]. Other myeloma drugs like daratumumab, elotuzumab, and carfilzomib are also being studied for their role in MM with EMD \[[@B3]\]. As far as the role of autologous hematopoietic stem cell transplantation (ASCT) is concerned, it provides survival advantages but is less efficacious in patients with extramedullary disease \[[@B10], [@B20]\]. In addition, with EMD, tandem ASCT does not give any survival benefit over single transplantation \[[@B21]\].

4. Conclusions {#sec4}
==============

Our discussion should underscore the fact that there is a dearth of prospective studies and no unanimous guidelines regarding the treatment of multiple myeloma with extramedullary disease. So, there might be great subjectivity and variability based on clinician preference. With the advent of new treatment options, the need for more studies becomes even more pertinent to ensure an evidence-based approach.

MM:

:   Multiple myeloma

EMD:

:   Extramedullary disease

TAH/BSO:

:   Total abdominal hysterectomy with bilateral salpingo-ophorectomy

ASCT:

:   Autologous stem cell transplantation.
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![(a) CT scan showing thyroid gland with large left lobe mass. (b) Sheets of monoclonal plasma cells infiltrating skeletal muscle fibers, H&E. (c) PET-CT showing 4.4 × 4.7 cm mass with central necrosis within the left thyroid lobe.](CRIHEM2019-7348504.001){#fig1}

![(a) PET-CT showing right breast nodules with FDG uptake. (b) Breast lesion consisting of monoclonal plasma cells, H&E. (c) Monoclonal plasma cells permeate the native breast lobules, H&E.](CRIHEM2019-7348504.002){#fig2}

###### 

Treatment regimens that can be used in multiple myeloma with extramedullary disease.

  ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stem cell transplantation eligible patients                                    Triplet induction therapy followed by ASCT, triplet consolidation therapy, and maintenance with lenalidomide at least
  Elderly patients not eligible for stem cell transplantation                    Bortezomib-melphalan-prednisone (VMP) or continuous lenalidomide-dexamethasone (Len-Dex)
  Very aggressive disease especially with multiple plasmacytomas                 VDT-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide) followed by ASCT if eligible and maintenance with bortezomib-based regimen
  Treatment modalities under study which may be used with traditional regimens   Pomalidomide, daratumumab, elotuzumab, carfilzomib
  ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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